Quick Answer
Karyopharm Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $60.54 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -3.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Karyopharm Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,657.3%.
- Historical annual values: Fiscal year 2025: $60.54 million | Fiscal year 2024: $62.48 million | Fiscal year 2023: $52.23 million | Fiscal year 2022: $135.19 million | Fiscal year 2021: $190.46 million | Fiscal year 2020: $85.92 million | Fiscal year 2019: $128.86 million | Fiscal year 2018: $118.02 million | Fiscal year 2017: $69.00 million | Fiscal year 2016: $49.66 million | Fiscal year 2015: $58.36 million | Fiscal year 2014: $150.61 million | Fiscal year 2013: $155.97 million | Fiscal year 2012: $391.0 thousand | Fiscal year 2011: $6.51 million | Fiscal year 2010: $3.45 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: